ReviewCancers2020
Genetics and Opioids: Towards More Appropriate Prescription in Cancer Pain.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Awareness about opioids crisis, policies and regulation of opioid stewardship at hospitals settings: a nationwide cross-sectional study among healthcare professionals from Pakistan.Substance abuse treatment, prevention, and policy · 2026Article
- The OPRM1 A118G Polymorphism Revisited: Recent Developments and Implications for Personalized Treatment.Current pain and headache reports · 2026Review
- Review
- Comparison of Pecto-Intercostal Fascial Block Vs Transversus Thoracic Plane Block and Their Pharmacogenomics for Pain Management After Sternotomy in Cardiac Surgery: A Narrative Review.Journal of pain research · 2026Review
- Observational
- Opioid Use in Cancer Pain Management: Navigating the Line Between Relief and Addiction.International journal of molecular sciences · 2025Review
- Diabetic neuropathy: cutting-edge research and future directions.Signal transduction and targeted therapy · 2025Review
- CYP2D6 Pharmacogenetics in Nigerian Sickle Cell Disease: Phase 1 of Implementing Pharmacogenomics Testing for Effective Care and Treatment in Africa (iPROTECTA) program.Gates open research · 2025Article
- Empowering Pharmacists: Strategies for Addressing the Opioid Crisis through a Public Health Lens.Pharmacy (Basel, Switzerland) · 2024Article
- Managing Severe Cancer Pain with Oxycodone/Naloxone Treatment: A Literature Review Update.Journal of personalized medicine · 2024Review
- The effects of OPRM1 118A>G on methadone response in pain management in advanced cancer at end of life.Scientific reports · 2024Review
- Pharmacogenetic landscape of pain management variants among Mediterranean populations.Frontiers in pharmacology · 2024Article
- How to Modulate Peripheral and Central Nervous System to Treat Acute Postoperative Pain and Prevent Pain Persistence.Current neuropharmacology · 2024Review
- Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of PreemptiveJournal of pain research · 2024Article
- Personalized Medicine in Cancer Pain Management.Journal of personalized medicine · 2023Review
- Pharmacogenomic profile of actionable molecular variants related to drugs commonly used in anesthesia: WES analysis reveals new mutations.Frontiers in pharmacology · 2023Article
- Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life.Scientific reports · 2022Article
- Wearable transcutaneous electrical nerve stimulation (actiTENS®) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trialTherapeutic advances in musculoskeletal disease · 2022Article
- Comparative analysis of the effects of opioids in angiogenesis.BMC anesthesiology · 2021Article
- A Global Survey on Opioid Stewardship Practices in Hospitals: A Cross-Sectional Pilot Study.Pharmacy (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioids are extensively used in patients with cancer pain; despite their efficacy, several patients can experience ineffective analgesia and/or side effects. Pharmacogenetics is a new approach to drug prescription based on the "personalized-medicine" concept, i.e., the ability of tailoring treatments to each individual's genetic/genomic profile. Pharmacogenetics aims to identify specific genetic variants that influence pharmacokinetics and pharmacodynamics of drugs, better determining their effectiveness/safety profile. Opioid response is a complex scenario, but some gene variants have shown a correlation with pain sensitivity, as well as with opioid metabolism and clinical efficacy/adverse events. Although questions remain unanswered, some of these gene variants may already be used to identify specific patients' phenotypes that are more prone to experience better clinical response (i.e., better analgesia and/or less adverse events). Once adopted, this approach to opioid prescription may improve a patient's outcome. This review summarizes the available data on genetic variants and opioid response: we will focus on basic pharmacogenetic and its impact in the clinical scenario discussing how they may lead to more appropriate opioid prescription in cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.